Eric Vangrevelinghe

Novartis (China) — China

Medicine · Health Sciences

22h-index1.7kcitations67works14.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cytokine Signaling Pathways and Interactions(25), Myeloproliferative Neoplasms: Diagnosis and Treatment(13), Computational Drug Discovery Methods(9), Chronic Lymphocytic Leukemia Research(8), Protein Kinase Regulation and GTPase Signaling(7)

Publications67 total

Discovery of NP3-742: A Structurally Diverse NLRP3 Inhibitor Identified through an Unusual Phenol Replacement
Journal of Medicinal Chemistry·2025
Discovery and Optimization of Selective Inhibitors of Large Tumor Suppressor Kinases LATS1 and 2 for In Vivo Investigation of the Hippo-YAP Pathway in Tissue Regeneration
Journal of Medicinal Chemistry·2025· 1 cited
Discovery of NP3-253, a Potent Brain Penetrant Inhibitor of the NLRP3 Inflammasome
Journal of Medicinal Chemistry·2024· 25 cited
Identification of TAK-756, A Potent TAK1 Inhibitor for the Treatment of Osteoarthritis through Intra-Articular Administration
Journal of Medicinal Chemistry·2024· 2 cited
NIBR-LTSi is a selective LATS kinase inhibitor activating YAP signaling and expanding tissue stem cells in vitro and in vivo
Cell stem cell·2024· 27 cited
Discovery of Potent, Orally Bioavailable, Tricyclic NLRP3 Inhibitors
Journal of Medicinal Chemistry·2024· 34 citedOpen Access
Design of a Supersoft Topical JAK Inhibitor, Which Is Effective in Human Skin but Rapidly Deactivated in Blood
Journal of Medicinal Chemistry·2023Open Access
Novel Concept for Super-Soft Topical Drugs: Deactivation by an Enzyme-Induced Switch into an Inactive Conformation
ACS Medicinal Chemistry Letters·2023· 1 citedOpen Access
Data from Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent
2023Open Access
Supplementary Table S3 from Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent
2023Open Access
Supplementary Table S2 from Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent
2023Open Access
Supplementary Table S1 from Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent
2023Open Access
Supplementary Table S2 from Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent
2023Open Access
Supplementary Table S3 from Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent
2023Open Access
Supplementary Figures, Methods, and References from Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent
2023Open Access
Data from Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent
2023Open Access
Supplementary Figures, Methods, and References from Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent
2023Open Access
Supplementary Table S1 from Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent
2023Open Access
Data from Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805
2023Open Access
Supplementary Data from Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Thomas Radimerski(16), Francesco Hofmann(13), Fabienne Baffert(13), Christoph Gaul(12), Catherine H. Régnier(12), Alain De Pover(11), Gisele Tavares(10), Carole Pissot‐Soldermann(10), Clemens Scheufler(8), Lorenza Wyder(8), Pascal Furet(7), Edgar Jacoby(6), Dirk Erdmann(6), Ross L. Levine(6), Rita Andraos(6), Joëlle Rubert(6), Gebhard Thoma(6), Hans‐Günter Zerwes(6), Nadja Kopp(5), David M. Weinstock(5)